The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / November / Unlocking the Multi-Omics Potential of a Blood Spot
Omics Omics Mass Spectrometry Liquid Chromatography

Unlocking the Multi-Omics Potential of a Blood Spot

Combining metabolite and lipid analysis could help researchers uncover more biochemical information from a single dried blood sample

By Jessica Allerton 11/20/2026 3 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: Unlocking the Multi-Omics Potential of a Blood Spot

At a Glance

CategoryDetail
ConditionDried blood spot (DBS) metabolite and lipid analysis
Key MechanismsA biphasic Folch-modeled extraction separates lipids into an organic phase and metabolites into an aqueous phase for LC-HRMS/MS analysis from one DBS.
Target PopulationResearch use with DBS specimens; potential diagnostic applications require further method development and clinical validation in samples from affected patients.
Care SettingLaboratory analysis of DBS, including research related to newborn screening; broader diagnostic use has not yet been clinically validated.

Key Highlights

  • The protocol analyzes metabolites and lipids from a single 10 µL DBS specimen.
  • Lower reconstitution volume was used to concentrate analytes and improve signal intensity.
  • Volumetric DBS devices were used to collect a fixed blood volume and reduce variability related to spot volume and hematocrit.
  • DBS results may not be directly comparable with plasma or serum reference values.
  • The authors state that further method development and clinical validation are needed before diagnostic application.

Guideline-Based Recommendations

Diagnosis

  • The described method is an analytical approach; the article does not provide diagnostic criteria or validated clinical cutoffs.

Management

  • The article does not provide treatment or disease-management recommendations.

Monitoring & Follow-up

  • Reliability and reproducibility were assessed by performing repeated DBS extractions from the same donors on different days and comparing results.

Risks

  • Metabolite and lipid concentrations can differ between DBS whole blood and plasma or serum, limiting direct comparison with reference values from other matrices.
  • Drying and storage may alter molecular profiles through oxidation, reduction, or other chemical changes.
  • Hematocrit and spot volume can contribute to variability; conventional non-volumetric cards may be affected by blood spreading and punch volume.

Patient & Prescribing Data

No patient treatment population or prescribing data are reported. The method was developed for DBS analysis, with potential future diagnostic use requiring validation in samples from affected patients.

No treatments or prescribing recommendations are discussed. The authors describe potential detection of multiple metabolic and lipid-related disorders from one low-volume specimen, pending further development and clinical validation.

Clinical Best Practices

  • Account for specimen matrix when interpreting results; DBS measurements may not be directly comparable with plasma or serum reference values.
  • Consider drying, storage, hematocrit, and spot volume as pre-analytical sources of variation.
  • Use volumetric DBS devices when a fixed blood volume is required; the described workflow used devices collecting 10 µL.
  • The described procedure used glass pipettes and tubes to minimize polyethylene glycol contamination.
  • Interpret molecular identifications in the context of the stated analytical workflow: metabolites were processed in MZmine and lipids annotated using LipidMatch.

Related Resources & Content

    This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

    Newsletters

    Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

    Newsletter Signup Image

    About the Author(s)

    Jessica Allerton

    Deputy Editor, The Pathologist

    More Articles by Jessica Allerton

    False

    Advertisement

    Recommended

    False

    Related Content

    The Analytical Scientist Innovation Awards 2024: #7
    Omics
    The Analytical Scientist Innovation Awards 2024: #7

    December 2, 2024

    4 min read

    Frank Steemers, co-founder and CSO of Scale Biosciences, tells us the story of ScalePlex – the 7th ranked innovation on this year’s Awards

    The Analytical Scientist Innovation Awards 2024: #4
    Omics
    The Analytical Scientist Innovation Awards 2024: #4

    December 5, 2024

    6 min read

    Thermo Fisher Scientific’s high-sensitivity mass spec for translational omics research – the Stellar MS – is ranked 4th in our annual Innovation Awards

    Let Me See That Brain
    Omics
    Let Me See That Brain

    December 9, 2024

    1 min read

    TRISCO sets a new standard for 3D RNA imaging, delivering high-resolution and uniform images to offer insights into brain function and anatomy

    The Analytical Scientist Innovation Awards 2024
    Omics
    The Analytical Scientist Innovation Awards 2024

    December 11, 2024

    10 min read

    Meet the products – and the experts – defining analytical innovation in 2024

    Affiliations:

    Specialties:

    Areas of Expertise:

    Contributions:

    False

    The Analytical Scientist
    Subscribe

    About

    • About Us
    • Work at Conexiant Europe
    • Terms and Conditions
    • Privacy Policy
    • Your Privacy Choices
    • Advertise With Us
    • Contact Us

    Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.